Effects of gamma-aminobutyric acid on diabetic etiopathogenesis

Abstract

Abstract: Diabetes mellitus is a frequent endocrine disorder disease and its etiopathogenesis is still not completely known, which is caused by several factors.In recent years gamma-aminobutyric acid was believed to have something to do with the formation of diabetes mellitus. The glutamic acid decarboxylase, which is one of the earlier autoantigens causing diabetes mellitus, is the synthetase inhibitor of gamma-aminobutyric acid.The relationship of gamma-aminobutyric acid, islets of langerhans and the central nervous system in diabetes mellitus was reviewed in this paper.

Key words: diabetes mellitus, etiopathogenesis, gamma-aminobutyric acid, glutamate decarboxylase

CLC Number:

R587.1

ZHOU Ji-yin, ZHOU Shi-wen. Effects of gamma-aminobutyric acid on diabetic etiopathogenesis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 739-742.

References

1 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Report of the expert committee on the diagnosis and classification of diabetes mellitus[J].Diabetes Care, 2003;26: S5-S20.
2 Gladkevich A, Korf J, Hakobyan VP, et al.The peripheral GABAergic system as a target in endocrine disorders[J].Auton Neurosci, 2006;124:1-8.
3 Yokota I, Shima K.GAD antibody in IDDM[J].Rinsho Byori, 1998;46:331-337.
4 Chessler SD, Simonson WT, Sweet IR, et al.Expression of the vesicular inhibitory amino acid transporter in pancreatic islet cells:distribution of the transporter within rat islets[J].Diabetes, 2002;51:1763-1771.
5 Maemura K, Yanagawa Y, Obata K, et al.Antigen-presenting cells expressing glutamate decarboxylase 67 were identified as epithelial cells in glutamate decarboxylase 67-GFP knock-in mouse thymus[J].Tissue Antigensw, 2006;67:198-206.
6 Baekkeskov S, Aanstoot HJ, Christgau S, et al.Identification of the 64K autoantigen in insulin-dependent diabetes as the GABAsynthesizing enzyme glutamic acid decarboxylase[J].Nature, 1990;347:151-156.
7 Michelsen BK, Petersen JS, Boel E, et al.Cloning, characterization, and autoimmune recognition of rat islet glutamic acid decarboxylase in insulin-dependent diabetes mellitus[J].Proc Natl Acad Sci USA, 1991;88:8754-8758.
8 Beales PE, Hawa M, Williams AJ, et al.Baclofen, a gammaaminobutyric acid-b receptor agonist, delays diabetes onset in the non-obese diabetic mouse[J].Acta Diabetol, 1995;32:53-56.
9 Kash SF, Condie BG, Baekkeskov S.Glutamate decarboxylase and GABA in pancreatic islets:lessons from knock-out mice [J].Horm Metab Res, 1999;31:340-344.
10 Nakagawa T, Yokozawa T, Kim HJ, et al.Protective effects of gamma-aminobutyric acid in rats with streptozotocin-induced diabetes[J].J Nutr Sci Vitaminol(Tokyo), 2005;51:278-282.
11 Saravia-Fernandez F, Faveeuw C, Blasquez-Bulant C, et al. Localization of gamma-aminobutyric acid and glutamic acid decarboxylase in the pancreas of the nonobese diabetic mouse[J]. Endocrinology, 1996;137:3497-3506.
12 Takamatsu K, Ohta T, Sato S, et al.Two diabetics with hemichorea-hemiballism and striatal lesions[J].No To Shinkei, 1995;47:167-172.
13 Duarte A, Santos M, Seica R, et al.Effect of oxidative stress on the uptake of GABA and glutamate in synaptosomes isolated from diabetic rat brain[J].Neuroendocrinology, 2000;72:179-186.
14 Tian J, Lu Y, Zhang H, et al.Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model[J].J Immunol, 2004;173:5298-5304.
15 Wendt A, Birnir B, Buschard K, et al.Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells[J].Diabetes, 2004;53: 1038-1045.
16 Uehara S, Muroyama A, Echigo N, et al.Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans[J].Diabetes, 2004;53:998-1006.
17 Adeghate E, Ponery AS.GABA in the endocrine pancreas: cellular localization and function in normal and diabetic rats[J]. Tissue Cell, 2002;34:1-6.
18 Quatraro A, Consoli G, Stante A, et al.Impaired insulin secretion in human diabetes mellitus.Effect of pharmacological activation of gamma-aminobutyric acid system[J].Acta Diabetol Lat, 1986;23:23-28.
19 Suckow A, Sweet I, Van-Yserloo B, et al.Identification and characterization of a novel isoform of the vesicular gamma-aminobutyric acid transporter with glucose-regulated expression in rat islets[J].JMol Endocrinol, 2006;36:187-199.
20 Wang C, Huang H, Kuo K, et al.Analysis of Puerariae radix and its medicinal preparations by capillary electrophoresis[J].J Chromatogr A, 1998;802:225-231.
21 Fink K, Zentner J, GothertM.Increased GABA release in the human brain cortex as a potential pathogenetic basis of hyperosmolar diabetic coma[J].J Neurochem, 1994;62:1476-1481.
22 Gomez R, Vargas CR, Wajner M, et al.Lower in vivo brain extracellular GABA concentration in diabetic rats during forced swimming[J].Brain Res, 2003;968:281-284.
23 Guyot LL, Diaz FG, O'Regan MH, et al.The effect of topical insulin on the release of excitotoxic and other amino acids from the rat cerebral cortex during streptozotocin-induced hyperglycemic ischemia[J].Brain Res, 2000;872:29-36.
24 Aerts L, Van Assche FA.Low taurine, gamma-aminobutyric acid and carnosine levels in plasma of diabetic pregnant rats: consequences for the offspring[J].J Perinat Med, 2001;29:81-84.
25 Guyot LL, Diaz FG, O'ReganMH, et al.The effect of streptozotocin-induced diabetes on the release of excitotoxic and other amino acids from the ischemic rat cerebral cortex[J].Neurosurgery, 2001;48:385-390.
26 Ohtani N, Ohta M, Sugano T.Microdialysis study of modification of hypothalamic neurotransmitters in streptozotocin-diabetic rats[J].J Neurochem, 1997;69:1622-1628.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[4]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[5]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[6]	WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
[7]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[8]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[9]	HUANG Hao, XIAO Fang, JIA Hong, WANG Xiaoshuang, DUAN Yating. miR-138-5p protects β cell function by regulating HIF-1α in gestational diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 489-497.
[10]	YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.
[11]	XU Ming, SHEN Zheng. Research progress on the mechanism of traditional Chinese insects' medicine treatment of diabetic neurological complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 597-600.
[12]	LI Zhuqing, JU Yinghui, CHEN Qingqing, MA Keke, LI Weiping. Protective effects of Astragaloside Ⅳ on early kidney damage in diabetes mellitus rats and its mechanisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 255-262.
[13]	ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.
[14]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[15]	LIU Chang, JIANG Daoli, LIU Xiaofang, XU Jia, WANG Lijue, WANG Qian, XU Ling, FANG Yi. Establishment of rat model of type 2 diabetes induced by streptozotocin combined with cerebral ischemic reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 518-525.